Budoprutug posts durable platelet responses in ITP including rituximab failures; whether higher doses and pMN data can anchor a registrational path is the deciding question

Climb Bio is a clinical-stage company developing a targeted therapy for immune thrombocytopenia, a blood disorder where the immune system attacks platelets, and the therapy is not yet approved.

Budoprutug, an anti-CD40L monoclonal antibody targeting B-cell-driven autoimmune disease, produced durable platelet responses in ITP patients at 250 mg including rituximab-refractory cases, with a subcutaneous formulation cleared in healthy volunteers. Whether higher-dose cohort data confirms a clean dose-response and supports a viable registrational design across ITP and primary membranous nephropathy determines the bull case. The trial base is still Phase 1b with small cohorts, and an increasingly crowded IgA nephropathy field creates pressure on the parallel CLYM116 program to deliver differentiated Phase 2 data.